Glycation does not modify bovine serum albumin (BSA)-induced reduction of rat aortic relaxation: the response to glycated and nonglycated BSA is lost in metabolic syndrome.
The effects of nonglycated bovine serum albumin (BSA) and advanced glycosylation end products of BSA (AGE-BSA) on vascular responses of control and metabolic syndrome (MS) rats characterized by hypertriglyceridemia, hypertension, hyperinsulinemia, and insulin resistance were studied. Albumin and in vitro prepared AGE-BSA have vascular effects; however, recent studies indicate that some effects of in vitro prepared AGEs are due to the conditions in which they were generated. We produced AGEs by incubating glucose with BSA for 60 days under sterile conditions in darkness and at 37 degrees C. To develop MS rats, male Wistar animals were given 30% sucrose in drinking water since weanling. Six month old animals were used. Blood pressure, insulin, triglycerides, and serum albumin were increased in MS rats. Contraction of aortic rings elicited with norepinephrine was stronger. There were no effects of nonglycated BSA or AGE-BSA on contractions in control or MS rats; however, both groups responded to L-NAME, an inhibitor of nitric oxide synthesis. Arterial relaxation induced using acetylcholine was smaller in MS rats. Nonglycated BSA and AGE-BSA significantly diminished relaxation in a 35% in the control group but the decrease was similar when using nonglycated BSA and AGE-BSA. This decrease was not present in the MS rats and was not due to increased RAGEs or altered biochemical characteristics of BSA. In conclusion, both BSA and AGE-BSA inhibit vascular relaxation in control artic rings. In MS rats the effect is lost possibly due to alterations in endothelial cells that are a consequence of the illness.
Rubio-Ruiz
Maria Esther
ME
Department of Physiology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Díaz-Díaz
Eulises
E
Cárdenas-León
Mario
M
Argüelles-Medina
Rabindranath
R
Sánchez-Canales
Patricia
P
Larrea-Gallo
Fernando
F
Soria-Castro
Elizabeth
E
Guarner-Lans
Verónica
V
D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000502:physiology*; D002417:Cattle; D005947:Glucose / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000494:pharmacology / Q000502:physiology*; D006031:Glycosylation; D066298:In Vitro Techniques; D008297:Male; D024821:Metabolic Syndrome / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012710:Serum Albumin, Bovine / Q000494:pharmacology / Q000502:physiology*; D014280:Triglycerides / Q000097:blood; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology*
D017127:Glycation End Products, Advanced; D014280:Triglycerides; C081628:advanced glycation end products-bovine serum albumin; D012710:Serum Albumin, Bovine; D005947:Glucose; D019331:NG-Nitroarginine Methyl Ester; D009638:Norepinephrine